Midostaurin and emerging FLT3 inhibitors for the treatment of adults with newly diagnosed acute myeloid leukemia with the FLT3 mutation

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Review of Precision Medicine and Drug Development

• Publication date

  2017-11-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/23808993.2017.1406798
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The Future of Targeting FLT3 Activation in AML

  2017cited by this paper
• Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis

  2017cited by this paper
• The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.

  2017cited by this paper
• Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study

  2017cited by this paper
• Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

  2017influential reference
• A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.

  2017cited by this paper
• The role of FLT3 inhibitors in the treatment of FLT3‐mutated acute myeloid leukemia

  2017cited by this paper
• Cancer statistics, 2017

  2017cited by this paper
• A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001.

  2017cited by this paper
• Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.

  2017influential reference
• Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia

  2016influential reference
• Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3‐ITD acute myeloid leukaemia in first complete remission

  2016cited by this paper
• Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.

  2016cited by this paper
• Midostaurin: an emerging treatment for acute myeloid leukemia patients

  2016cited by this paper
• Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3-Itd-Mutated Acute Myeloid Leukemia (AML)

  2016cited by this paper
• Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML)

  2016cited by this paper
• Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial

  2016cited by this paper
• Activation of HIV-1 expression in latently infected CD4+ T cells by the small molecule PKC412

  2016cited by this paper
• Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

  2015influential reference
• A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.

  2015influential reference
• A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations

  2015cited by this paper
• Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

  2015cited by this paper
• A Phase 1/2, Open-Label, Dose-Escalation Study of Midostaurin in Pediatric Patients (Pts) with Relapsed or Refractory (R/R) Acute Leukemia: Final Results of Study ITCC-024 (CPKC412A2114)

  2015cited by this paper
• Inhibition of c-Kit by tyrosine kinase inhibitors

  2015cited by this paper
• Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia.

  2014cited by this paper
• Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML

  2014cited by this paper
• Crenolanib is a selective type I pan-FLT3 inhibitor

  2014influential reference
• Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.

  2013cited by this paper
• Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.

  2013cited by this paper
• Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers

  2013cited by this paper
• Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.

  2013cited by this paper
• Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.

  2013cited by this paper
• Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia

  2013influential reference
• Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

  2013cited by this paper
• Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia

  2012cited by this paper
• Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation

  2012cited by this paper
• Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

  2012cited by this paper
• Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

  2012cited by this paper
• Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

  2012cited by this paper
• Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors

  2012cited by this paper
• Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia

  2011influential reference
• Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.

  2011cited by this paper
• Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

  2011cited by this paper
• FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.

  2011cited by this paper
• Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

  2010influential reference
• AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

  2009cited by this paper
• A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.

  2009cited by this paper
• A Mechanism-Based Population Pharmacokinetic Model for Characterizing Time-Dependent Pharmacokinetics of Midostaurin and its Metabolites in Human Subjects

  2008cited by this paper
• Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.

  2008cited by this paper
• Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.

  2007cited by this paper
• Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.

  2007cited by this paper
• Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.

  2006cited by this paper
• Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.

  2006cited by this paper
• Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

  2005cited by this paper
• A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

  2005cited by this paper
• A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition.

  2005cited by this paper
• Acute myeloid leukemia

  2004cited by this paper
• SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

  2003cited by this paper
• Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

  2002influential reference
• Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

  2001influential reference
• PKC412--a protein kinase inhibitor with a broad therapeutic potential.

  2000cited by this paper
• Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent.

  1999cited by this paper
• Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias.

  1996cited by this paper
• Cancer statistics

  1989cited by this paper

• Identification of Pyrrolo[2,3-d]pyrimidine-Based Dual MERTK and FLT3 Inhibitor: Hit-to-Lead, Machine Learning, Modeling, Synthesis, and Biological Evaluation.

  2026cites this paper
• Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations.

  2021cites this paper